Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 1/2005

01-01-2005 | Review Article

Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain

Authors: Philip H. Elsinga, PhD, N. Harry Hendrikse, PhD, Joost Bart, PhD, Aren van Waarde, PhD, Willem Vaalburg, PhD

Published in: Molecular Imaging and Biology | Issue 1/2005

Login to get access

Abstract

The permeability of the blood–brain barrier (BBB) is one of the factors determining the bioavailability of drugs in the brain. The BBB only allows passage of lipophilic drugs by passive diffusion. However, some lipophilic drugs hardly enter the brain. The transmembrane protein P-glycoprotein (P-gp) is one of the carrier systems that is responsible for transportation of drugs out of the brain. P-Glycoprotein affects the pharmacokinetics of many drugs and can be inhibited by administration of modulators or competitive substrates. Identification and classification of central nervous system (CNS) drugs as P-gp substrates or inhibitors are of crucial importance in drug development. Positron emission tomography (PET) studies can play an important role in the screening process as a follow-up of high-throughput in vitro assays. Several rodent studies have shown the potential value of PET to measure the effect of P-gp on the pharmacokinetics and brain uptake of radiolabeled compounds. P-Glycoprotein-mediated effects were observed for two 5-HT1a receptor ligands, [18F]MPPF vs. [carbonyl-11C]WAY100635. Under control conditions, the specific brain uptake of [18F]MPPF is five- to eightfold lower than that of [11C]WAY100635. After cyclosporin A (CsA) modulation, [18F]MPPF uptake in the rat brain increased five- to tenfold. Cerebral uptake of [carbonyl-11C]WAY100635 was also increased by modulation, but in general the increase was lower than that observed for [18F]MPPF (two- to threefold). Brain uptake of the β-adrenergic receptor ligands [11C]carazolol and [18F]fluorocarazolol was increased in P-gp knockout mice and CsA-treated rats. Both the specific and nonspecific binding of [18F]fluorocarazolol were doubled by CsA. Cerebral uptake of [11C]carazolol in rats was much lower than that of [18F]fluorocarazolol and no specific binding was measured. After CsA modulation, the uptake of [11C]carazolol increased five- to sixfold, but this uptake was not receptor-mediated. Quantitative PET studies in rodents on P-gp functionality demonstrated a dose-dependent increase of radioligands after administration of CsA. Studies with [11C]verapamil and [11C]carvedilol showed that complete modulation was achieved at 50 mg/kg CsA. The distribution volume of [11C]carvedilol increased from 0.25 in the control study to 1.0 after full modulation with CsA. By quantitative PET measurement of P-gp function, the dose of modulators required to increase the concentration of CNS drugs may be determined, which may result in improved drug therapy.
Literature
1.
Bradbury, MW 1985The blood–brain barrier. Transport across the cerebral endotheliumCirc Res57213222
2.
Alberts, B, Bray, D, Lewis, J 1989Molecular biology of the cell2nd ednGarland Publishing, IncNew York
3.
Bradbury, MW 1993The blood–brain barrierExp Physiol78453472
4.
Pardridge, WM 1995Transport of small molecules through the blood–brain barrier: Biology and methodologyAdv Drug Deliv Rev15536CrossRef
5.
Pardridge, WM 1995Vector-mediated peptide drug delivery to the brainAdv Drug Deliv Rev15109146CrossRef
6.
Abbott, NJ, Romero, IA 1996Transporting therapeutics across the blood–brain barrierMol Med Today2106113CrossRef
7.
Begley, DJ 1996The blood–brain barrier: Principles for targeting peptides and drugs to the central nervous systemJ Pharm Pharmacol48136146
8.
Johansson, BB 1990The physiology of the blood–brain barrierAdv Exp Med Biol2742539
9.
Drewes, LR 1999What is the blood–brain barrier? A molecular perspective. Cerebral vascular biologyAdv Exp Med Biol474111122
10.
Begley, DJ 1992The interaction of some centrally active drugs with the blood–brain barrier and circumventricular organsProg Brain Res91163169
11.
Borst, P, Schinkel, AH 1996What have we learnt thus far from mice with disrupted P-glycoprotein genes?Eur J Cancer32A985990CrossRefPubMed
12.
Hughes, CS, Vaden, SL, Manaugh, CA 1998Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in ratsJ Neurooncol374554CrossRef
13.
Schinkel, AH, Wagenaar, E, Mol, CA 1996P-Glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugsJ Clin Invest9725172524PubMed
14.
Asperen, J, Schinkel, AH, Beijnen, JH 1996Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient MiceJ Natl Cancer Inst88994999
15.
Asperen, J, Mayer, U, Tellingen, O 1997The functional role of P-glycoprotein in the blood–brain barrierJ Pharm Sci86881884CrossRefPubMed
16.
Kartner, N, Riordan, JR, Ling, V 1983Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell linesScience22112851288
17.
Gottesman, MM, Pastan, I 1993Biochemistry of multidrug resistance mediated by the multidrug transporterAnn Rev Biochem62385427CrossRef
18.
Schinkel, AH 1997The physiological function of drug-transporting P-glycoproteinsSemin Cancer Biol8161170CrossRef
19.
Bart, J, Groen, HJM, Hendrikse, NH, Graaf, WTA, Vaalburg, W, Vries, EGE 2000The blood–brain barrier and oncology: New insights into function and modulationCancer Treat Rev26449462CrossRef
20.
Löscher, W, Potschka, H 2002Role of multidrug transporters in pharmacoresistance to antiepileptic drugsJ Pharmacol Exp Ther301714CrossRef
21.
Hofsli, E, Nissen-Meyer, J 1990Reversal of multidrug resistance by lipophilic drugsCancer Res5039974002
22.
Pearce, HL, Winter, MA, Beck, WT 1990Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistanceAdv Enzyme Regul30357373CrossRef
23.
Jette, L, Murphy, GF, Leclerc, JM 1995Interaction of drugs with P-glycoprotein in brain capillariesBiochem Pharmacol5017011709CrossRef
24.
Sharom, FJ 1997The P-glycoprotein efflux pump: How does it transport drugs?J Membr Biol160161175CrossRef
25.
Ueda, K, Taguchi, Y, Morishima, M 1997How does P-glycoprotein recognize its substrates?Semin Cancer Biol8151159CrossRef
26.
Pawagi, AB, Wang, J, Silverman, M 1994Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificityJ Mol Biol235554564CrossRef
27.
Ekins, S, Kim, RB, Leake, BF,  et al. 2002Three-dimensional quantitative structure–activity relationships of inhibitors of P-glycoproteinMol Pharmacol61964973CrossRef
28.
Pajeva, IK, Wiese, M 2002Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: Explanation of structural variety (hypothesis)J Med Chem4556715686CrossRef
29.
Niederberger, W, Lemaire, M, Maurer, G 1983Distribution and binding of cyclosporine in blood and tissuesTransplant Proc1524192421
30.
Greenwood, J 1992Characterization of a rat retinal endothelial cell culture and the expression of P-glycoprotein in brain and retinal endothelium in vitroJ Neuroimmunol39123132CrossRef
31.
Cordon-Cardo, C, O’Brien, JP, Casals, D 1989Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sitesProc Natl Acad Sci U S A86695698
32.
Sugawara, I, Hamada, H, Tsuruo, T 1990Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cordJpn J Cancer Res81727730
33.
Beaulieu, E, Demeule, M, Ghitescu, L 1997P-Glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brainBiochem J326539544
34.
Golden, PL, Pardridge, WM 1999P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillariesBrain Res819143146CrossRef
35.
Tatsuta, T, Naito, M, Oh-hara, T 1992Functional involvement of P-glycoprotein in blood–brain barrierJ Biol Chem2672038320391
36.
Thiebaut, F, Tsuruo, T, Hamada, H, Gottesman, MM, Pastan, I, Willingham, MC 1987Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissuesProc Natl Acad Sci U S A8477357738PubMed
37.
Metha, BM, Levchenko, A, Rosa, E, Kim, SW, Winnick, S, Zhang, JJ, Kalaigian, H, Larson, SM 1996Evaluation of carbon-14-colchicine biodistribution with whole-body quantitative autoradiography in colchicine-sensitive and -resistant xenograftsJ Nucl Med37312314
38.
Schwab, D, Fischer, H, Tabatabaei, A, Poli, S, Huwyler, J 2003Comparison of in vitro P-glycoprotein screening assays: Recommendations for their use in drug discoveryJ Med Chem4617161725CrossRef
39.
Hendrikse, NH, Schinkel, AH, Vries, EGE 1998Complete in vivo reversal of P-glycoprotein pump function in the blood–brain barrier visualised with positron emission tomographyBr J Pharmacol12414131418
40.
Levchenko, A, Mehta, BM, Lee, JB,  et al. 2000Evaluation of [11C]colchicine for PET imaging of multiple drug resistanceJ Nucl Med41493501
41.
Elsinga, PH, Franssen, EJ, Hendrikse, NH,  et al. 1996Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PETJ Nucl Med3715711575
42.
Lewis, JS, Dearling, JL, Sosabowsli, JK,  et al. 2000Copper bis(diphosphine) complexes: Radiopharmaceuticals for the detection of multidrug resistance in tumours by PETEur J Nucl Med27638646CrossRef
43.
Packard, AB, Kronauge, JF, Barbarics, E, Kiani, S, Treves, ST 2002Synthesis and biodistribution of a lipophilic 64Cu-labeled monocationic copper (II) complexNucl Med Biol29289292CrossRef
44.
Passchier, J, Lawrie, KWM, Bender, D, Fellows, I, Gee, AD 2003[11C]Loperamide as highly sensitive PET probe for measuring changes in P-glycoprotein functionalityJ Lab Comp Radiopharm46S94Abstract
45.
Kurdziel, KA, Kiesewetter, DO, Carson, RE, Eckelman, WC, Herscowitch, P 2003Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primatesJ Nucl Med4413301339
46.
Passchier, J, Waarde, A, Doze, P, Elsinga, PH, Vaalburg, W 2000Influence of P-glycoprotein on brain uptake of [18F]MPPF in ratsEur J Pharmacol407273280CrossRef
47.
Berridge, MS, Cassidy, EH, Terris, AH, Vesselle, JM 1992Preparation and in vivo binding of [11C]carazolol, a radiotracer for the β-adrenergic receptorNucl Med Biol19563569
48.
Doze, P, Waarde, A, Elsinga, PH, Loenen-Weemaes, AM, Willemsen, ATM, Vaalburg, W 1998Validation of S-1′-[18F]fluorocarazolol for in vivo imaging and quantification of cerebral β-adrenoceptorsEur J Pharmacol353215226CrossRef
49.
Elsinga, PH, Vos, MG, Waarde, A,  et al. 1996(S,S)- and (S,R)-1′-[18F]fluorocarazolol, ligands for the visualization of pulmonary β-adrenergic receptors with PETNucl Med Biol23159167CrossRef
50.
Zheng, LB, Berridge, MS, Ernsberger, P 1994Synthesis, binding properties, and 18F labeling of fluorocarazolol, a high-affinity β-adrenergic receptor antagonistJ Med Chem3732193230
51.
Waarde, A, Visser, TJ, Elsinga, PH,  et al. 1997Imaging β-adrenoceptors in the human brain with (S)-1′-[18F]fluorocarazololJ Nucl Med38934939
52.
Doze, P, Waarde, A, Elsinga, PH, Hendrikse, NH, Vaalburg, W 2000Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood–brain barrierSynapse366674CrossRef
53.
Grimm, LJ, Blendy, JA, Kellar, KJ, Perry, DC 1992Chronic reserpine administration selectively up-regulates β1- and α1b-adrenergic receptors in rat brain: An autoradiographic studyNeuroscience477786CrossRef
54.
Innis, RB, Correa, FMA, Snyder, SH 1979Carazolol, an extremely potent β-adrenergic blocker: Binding to β-receptors in brain membranesLife Sci2422552264CrossRef
55.
Golden, PL, Pardridge, WM 2000Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brainCell Mol Neurobiol20165181CrossRef
56.
Klohs, WD, Steinkampf, RW, Havlick, MJ, Jackson, RC 1986Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: Reversal by calcium blockers and calmodulin antagonistsCancer Res4643524356
57.
Hendrikse, NH, Vries, EGE, Eriks-Fluks, E,  et al. 1999A new in vivo method to study P-glycoprotein transport in tumors and the blood–brain barrierCancer Res5924112416
58.
Bart J, Willemsen ATM, Groen HJM, et al. (2003) Quantitative assessment of P-glycoprotein function in the rat blood–brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage (in press)
59.
Martin, SK, Oduola, AM, Milhous, WK 1987Reversal of chloroguine resistance in Plasmodium falciparum by verapamilScience235899901
60.
Hansch, C, Leo, A, Hoekman, D 1995Exploring QSAR: Hydrophobic, electronic, and steric constantsAmerican Chemistry SocietyWashington, DC
61.
Dishino, DD, Welch, MJ, Kilbourn, MR, Raichle, ME 1983Relationship between lipophilicity and brain extraction of 11C-labeled radiopharmaceuticalsJ Nucl Med2410301038
62.
Buchwald, P, Bodor, N 1998Octanol–water partition: Searching for predictive modelsCurr Med Chem5353380
63.
Jonsson, O, Behnam-Motlagh, P, Persson, M, Henriksson, R, Grankvist, K 1999Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activityBiochem Pharmacol5818011806CrossRef
64.
Doze, P, Elsinga, PH, Maas, B, Waarde, A, Wegman, T, Vaalburg, W 2002Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PETNeurochem Int40145155CrossRef
65.
Schaefer, WH, Politowski, J, Hwang, B 1998Metabolism of carvedilol in dogs, rats, and miceDrug Metab Dispos26958969
66.
Neugebauer, G, Neubert, P 1991Metabolism of carvedilol in manEur J Drug Metab Pharmacokinet16257260
67.
Neuhoff, S, Langguth, P, Dressler, C, Andersson, TB, Regardh, CG, Spahn-Langguth, H 2000Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolitesInt J Clin Pharmacol Ther38168179
68.
List, AF, Kopecky, KJ, Willman, CL,  et al. 2001Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group studyBlood9832123220CrossRef
69.
Boote, DJ, Dennis, IF, Twentyman, PR,  et al. 1996Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancerJ Clin Oncol14610618
70.
Rowinsky, EK, Smith, L, Wang, YM,  et al. 1998Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRPJ Clin Oncol1629642976PubMed
71.
Damiani, D, Michieli, M, Ermacora, A,  et al. 1998Adjuvant treatment with cyclosporin a increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemiaLeukemia1212361240CrossRef
72.
Newman, MJ, Rodarte, JC, Benbatoul, KD,  et al. 2000Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistanceCancer Res6029642972PubMed
73.
Sparreboom, A, Planting, AS, Jewell, RC,  et al. 1999Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoproteinAnticancer Drugs10719728PubMed
74.
Mistry, P, Stewart, AJ, Dangerfield, W,  et al. 2001In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator XR9576Cancer Res61749758
75.
Toppmeyer, D, Seidman, AD, Pollak, M,  et al. 2002Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxelClin Cancer Res8670678
76.
Mickley, LA, Lee, JS, Weng, Z,  et al. 1998Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines and human tumorsBlood117491756
77.
Siddiqui, A, Kerb, R, Weale, ME,  et al. 2003Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1N Engl J Med34814421448CrossRefPubMed
78.
Brinkmann, U, Roots, I, Eichelbaum, M 2001Pharmacogenetics of the human drug-transporter gene MDR1: Impact of polymorphisms on phamacotherapyDDT6835839
Metadata
Title
Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain
Authors
Philip H. Elsinga, PhD
N. Harry Hendrikse, PhD
Joost Bart, PhD
Aren van Waarde, PhD
Willem Vaalburg, PhD
Publication date
01-01-2005
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 1/2005
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-005-0951-x

Other articles of this Issue 1/2005

Molecular Imaging and Biology 1/2005 Go to the issue

Review Article

A Computational Positron Emission Tomography Simulation Model for Imaging β-Amyloid in Mice

Review Article

Imaging the Dopamine System with In Vivo [11C]raclopride Displacement Studies: Understanding the True Mechanism

Editorial

Firing Up the Innovation Engine

Review Article

Positron Emission Tomography Imaging of Small Animals in Anticancer Drug Development

Review Article

Noninvasive Imaging of Cardiac Gene Expression and Its Future Implications for Molecular Therapy

Editorial

SNIDD Special Issue